再燃前立腺癌に対するEstramustine phosphate・Vinblastine併用療法の検討

概要

論文の詳細を見る
再燃前立腺癌13例に対してEMP・VBL併用療法を実施した.初診時よりPSAが正常であった1例は頸部・縦隔リンパ節転移の著明な縮小を認めた.他の12例のうち5例でPSAが50%以上減少した.本療法が生存期間の延長に寄与している結果は得られなかったWe evaluated the efficacy of the combination of estramustine phosphate and vinblastine in 13 patients with hormone-refractory prostate cancer. Of 12 patients with an elevated prostate specific antigen (PSA) level at the start of treatment, 5 (42%) had a greater than 50% decrease in PSA level. In a patient with cervical and mediastinal lymph node metastases, about a 57% decrease was observed in bidimensional measurement. Side effects were mild and manageable. The survival rate was not significantly different between patients who showed a greater than 50% decrease in PSA levels or regression of lymph node metastases versus the other patients.